Generic Relistor Availability
Last updated on Jun 11, 2025.
Relistor is a brand name of methylnaltrexone, approved by the FDA in the following formulation(s):
RELISTOR (methylnaltrexone bromide - solution;subcutaneous)
-
Manufacturer: SALIX PHARMS
Approval date: April 24, 2008
Strength(s): 12MG/0.6ML (12MG/0.6ML) [RLD] [AP] -
Manufacturer: SALIX PHARMS
Approval date: September 27, 2010
Strength(s): 8MG/0.4ML (8MG/0.4ML) [RLD], 12MG/0.6ML (12MG/0.6ML) [RLD]
RELISTOR (methylnaltrexone bromide - tablet;oral)
-
Manufacturer: SALIX
Approval date: July 19, 2016
Strength(s): 150MG [RLD]
Is there a generic version of Relistor available?
A generic version of Relistor has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Relistor and have been approved by the FDA:
methylnaltrexone bromide solution;subcutaneous
-
Manufacturer: MYLAN LABS LTD
Approval date: May 28, 2025
Strength(s): 12MG/0.6ML (12MG/0.6ML) [AP]
Note: No generic formulation of the following product is available.
- methylnaltrexone bromide - tablet;oral
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Relistor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Oral formulations and lipophilic salts of methylnaltrexone
Patent 10,307,417
Issued: June 4, 2019
Inventor(s): Shah Syed M. & Diorio Christopher Richard & Ehrnsperger Eric C. & Meng Xu & Al Shareffi Kadum A. & Cohen Jonathan Marc
Assignee(s): Wyeth, LLCThe present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Patent expiration dates:
- March 10, 2031✓
- March 10, 2031
-
Oral formulations and lipophilic salts of methylnaltrexone
Patent 10,376,505
Issued: August 13, 2019
Inventor(s): Shah Syed M. & Diorio Christopher Richard & Ehrnsperger Eric C. & Meng Xu & Al Shareffi Kadum A. & Cohen Jonathan Marc
Assignee(s): Wyeth, LLCThe present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Patent expiration dates:
- March 10, 2031✓
- March 10, 2031
-
Peripheral opioid receptor antagonists and uses thereof
Patent 8,247,425
Issued: August 21, 2012
Inventor(s): Bazhina Nataliya & Donato & III George Joseph & Fabian Steven R. & Lokhnauth John & Megati Sreenivasulu & Melucci Charles & Ofslager Christian & Patel Niketa & Radebaugh Galen & Shah Syed M. & Szeliga Jan & Zhang Huyi & Zhu Tianmin
Assignee(s): WyethThe present invention provides a compound of formula I:
Patent expiration dates:
- December 31, 2030✓
- December 31, 2030
-
Peripheral opioid receptor antagonists and uses thereof
Patent 8,420,663
Issued: April 16, 2013
Inventor(s): Bazhina Nataliya & Donato & III George Joseph & Fabian Steven R. & Lokhnauth John & Megati Sreenivasulu & Melucci Charles K. & Ofslager Christian & Patel Niketa & Radebaugh Galen & Shah Syed M. & Szeliga Jan & Zhang Huyi & Zhu Tianmin
Assignee(s): WyethThe present invention provides a compound of formula I:
Patent expiration dates:
- September 30, 2029✓
- September 30, 2029
-
Oral formulations and lipophilic salts of methylnaltrexone
Patent 8,524,276
Issued: September 3, 2013
Inventor(s): Shah Syed M. & Diorio Christopher Richard & Ehrnsperger Eric C. & Meng Xu & Al Shareffi Kadum A. & Cohen Jonathan Marc
Assignee(s): Wyeth, LLCThe present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Patent expiration dates:
- March 10, 2031✓
- March 10, 2031
-
Peripheral opioid receptor antagonists and uses thereof
Patent 8,822,490
Issued: September 2, 2014
Inventor(s): Bazhina Nataliya & Donato & III George Joseph & Fabian Steven R. & Lokhnauth John & Megati Sreenivasulu & Melucci Charles & Ofslager Christian & Patel Niketa & Radebaugh Galen & Shah Syed M. & Szeliga Jan & Zhang Huyi & Zhu Tianmin
Assignee(s): Wyeth LLCThe present invention provides a compound of formula I:
Patent expiration dates:
- September 30, 2029✓✓
- September 30, 2029
-
Oral formulations and lipophilic salts of methylnal trexone
Patent 8,956,651
Issued: February 17, 2015
Inventor(s): Shah Syed M. & Diorio Christopher Richard & Ehrnsperger Eric C. & Meng Xu & Al Shareffi Kadum A. & Cohen Jonathan Marc
Assignee(s): Wyeth, LLCThe present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Patent expiration dates:
- March 10, 2031✓
- March 10, 2031
-
Peripheral opioid receptor antagonists and uses thereof
Patent 9,180,125
Issued: November 10, 2015
Inventor(s): Bazhina Nataliya & Donato & III George Joseph & Fabian Steven R. & Lokhnauth John & Megati Sreenivasulu & Melucci Charles & Ofslager Christian & Patel Niketa & Radebaugh Galen & Shah Syed M. & Szeliga Jan & Zhang Huyi & Zhu Tianmin
Assignee(s): Wyeth, LLCThe present invention provides a compound of formula I:
Patent expiration dates:
- September 30, 2029✓✓
- September 30, 2029
-
Oral formulations and lipophilic salts of methylnaltrexone
Patent 9,314,461
Issued: April 19, 2016
Inventor(s): Shah Syed M. & Diorio Christopher Richard & Ehrnsperger Eric C. & Meng Xu & Al Shareffi Kadum A. & Cohen Jonathan Marc
Assignee(s): Wyeth, LLCThe present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Patent expiration dates:
- March 10, 2031✓
- March 10, 2031
-
Peripheral opioid receptor antagonists and uses thereof
Patent 9,492,445
Issued: November 15, 2016
Inventor(s): Bazhina Nataliya & Donato & III George Joseph & Fabian Steven R. & Lokhnauth John & Megati Sreenivasulu & Melucci Charles & Ofslager Christian & Patel Niketa & Radebaugh Galen & Shah Syed M. & Szeliga Jan & Zhang Huyi & Zhu Tianmin
Assignee(s): Wyeth, LLCThe present invention provides a compound of formula I:
Patent expiration dates:
- September 30, 2029✓✓
- September 30, 2029
-
Peripheral opioid receptor antagonists and uses thereof
Patent 9,724,343
Issued: August 8, 2017
Inventor(s): Bazhina Nataliya & Donato & III George Joseph & Fabian Steven R. & Lokhnauth John & Megati Sreenivasulu & Melucci Charles & Ofslager Christian & Patel Niketa & Radebaugh Galen & Shah Syed M. & Szeliga Jan & Zhang Huyi & Zhu Tianmin
Assignee(s): Wyeth, LLCThe present invention provides a compound of formua I:
Patent expiration dates:
- September 30, 2029✓✓
- September 30, 2029
More about Relistor (methylnaltrexone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (61)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: peripheral opioid receptor antagonists
- Breastfeeding
- En español
Patient resources
- Relistor drug information
- Relistor (Methylnaltrexone Subcutaneous) (Advanced Reading)
- Relistor (Methylnaltrexone bromide Oral) (Advanced Reading)
Professional resources
Related treatment guides
Related/similar drugs
Amitiza
Amitiza (lubiprostone) is used to treat chronic constipation and irritable bowel syndrome with ...
Movantik
Movantik reduces constipation caused by opioid pain medicine used to treat severe chronic pain. It ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Symproic
Symproic (naldemedine) is used to treat constipation caused by opioid pain medicine. Symproic is ...
Naldemedine
Naldemedine is used for constipation, opioid-induced constipation
Naloxegol
Naloxegol is used for constipation, constipation, chronic, constipation, drug induced ...
Lubiprostone
Lubiprostone is used for chronic idiopathic constipation, constipation, irritable bowel syndrome ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
| AP | Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
